AMA CPT® Assistant - 2020 Issue 3 (March)
Coding Update: PALB2 Gene Test (March 2020)
March 2020 page 13 Coding Update: PALB2 Gene Test For 2020, two new codes (81307, 81308) were established in the Pathology and Laboratory/Molecular Pathology subsection of the Current Procedural Terminology (CPT®) code set to describe PALB2 gene analysis as an additional partner and localizer for BRCA2, which is a gene that encodes for proteins that suppress tumors. Prior to 2020, this genetic analysis was reported using Tier 2 code 81406, which did not include testing for known familial variants. However, the frequency of testing for mutations of this gene has sufficiently increased to warrant Tier 1 status for...
Subscribe or sign in to view the full article.
Article Overview
This article explains a 2020 CPT coding update for PALB2 gene testing within molecular pathology. It is aimed at coding professionals, laboratory staff, and revenue cycle teams who need to understand the scope of the update, the types of gene analysis discussed, and the clinical contexts referenced in the guidance.
Why This Topic Matters
Accurate interpretation of this update helps support consistent reporting of PALB2-related molecular pathology services and align laboratory documentation with the revised CPT framework.
Article Sections
-
Molecular Pathology
Introduces the molecular pathology context for the update and identifies the general testing scenarios discussed for PALB2-related services.
-
Clinical Example (81307) / Description of Procedure (81307)
Presents a representative clinical scenario and corresponding procedural context associated with one of the new PALB2 testing codes.
-
Clinical Example (81308) / Description of Procedure (81308)
Presents a representative clinical scenario and corresponding procedural context associated with the other new PALB2 testing code.
What You Will Learn
- How the 2020 CPT update relates to PALB2 gene analysis
- What general molecular pathology topics are covered in the update
- What kinds of clinical scenarios are used to illustrate the coding change
- How the article frames full-gene analysis versus familial-variant testing at a high level
Who Should Read This
- Medical coders
- Laboratory billing staff
- Pathology coding staff
- Revenue cycle teams
- Genetic testing laboratories
Codes Discussed
Subscribe or sign in to view the full article.


Quick, Current, Complete - www.findacode.com